



**American Water Works
Association**

Utility Member Benefit

Government Affairs Office
1300 Eye Street NW
Suite 701W
Washington, DC 20005
T 202.628.8303
F 202.628.2846

Headquarters
6666 West Quincy Avenue
Denver, CO 80235-3098
Washington, DC 20005
T 303.794.7711
F 303.795.1989
www.awwa.org

The Authoritative Resource on Safe Water®

Regulatory Alert

**TO: AWWA Leadership
All Utilities**

FROM: AWWA Government Affairs

DATE: September 23, 2009

Who:	US Environmental Protection Agency
What:	Contaminant Candidate List (CCL3), expanded to include 10 pharmaceutical compounds
When:	Signed yesterday

Peter Silva, Assistant Administrator for Water for the U.S. Environmental Protection Agency (EPA), yesterday signed the final drinking water Contaminant Candidate List 3 (CCL3). This final CCL3 contains 116 contaminants versus the 104 contained in a draft published in February 2008.

Among the changes from the last draft is the inclusion of 10 pharmaceutical compounds, a development that may be of particular interest to media.

The CCL is used as the starting point for the regulatory development process, and EPA will select contaminants off the final CCL3 to make its third round of regulatory determinations for at least five contaminants in 2013.

The changes between the draft and final CCL3 are:

Added to the CCL3

- The pharmaceuticals added include:
 - One antibiotic: erythromycin.
 - Nine hormones: 17 alpha-estradiol, 17 beta-estradiol, equilenin, equilin, estriol, estrone, ethinyl estradiol, mestranol, and norethindrone
- One perfluorinated compound: perfluorooctane sulfonic acid (PFOS)
- Two potential disinfection by-products: chlorate and bromochloromethane (Halon 1011)

- Three pathogens: Adenovirus, Enterovirus, and *Mycobacterium avium*

Removed from the CCL3

- Two pesticides no longer in use in the United States: nitrofen and ethion
- Two pathogens: *Vibrio cholera* and *Entamoeba histolytica*

EPA also added a table on data needs for CCL3 contaminants in order to make future regulatory determinations. This table provides a general characterization of the health effects, occurrence, and analytical method data needs.

The pre-publication version of this notice can be found on the EPA website at http://www.epa.gov/safewater/ccl/pdfs/ccl3_docs/pre-fr_ccl3.pdf

A paper was published in the September issue of *Journal AWWA* on a risk index approach to organizing and visualizing all of the occurrence and toxicity data for the CCL3 contaminants. This approach has the potential to inform future decisions for the third Unregulated Contaminant Monitoring Rule (UCMR3) and the third round of regulatory determinations. This project was a partnership between the Water Industry Technical Action Fund (WITAF) and the Water Research Foundation and the paper can be found on the AWWA website at <http://www.awwa.org/publications/AWWAJournalArticle.cfm?itemnumber=50710>

Consumer information related to pharmaceutical compounds in drinking water is available here: <http://www.drinktap.org/consumerdnn/Home/WaterInformation/WaterQuality/PharmaceuticalsPPCPs/tabid/73/Default.aspx>

More information on endocrine disruptors and pharmaceutical compounds is available at <http://www.awwa.org/Resources/topicspecific.cfm?ItemNumber=3647&navItemNumber=32969>

As always, please contact your AWWA Washington Office (202-628-8303) or AWWA Public Affairs (303-347-6140) if you have questions or comments.

###